Glioblastoma (GBM), one of the most aggressive types of brain cancer, is one of the greatest challenges for medicine, both ...

Therapeutics announced plans for a Phase 2 trial evaluating the combination of stenoparib with temozolomide, a DNA-alkylating ...

Allarity Therapeutics has announced a Phase 2 clinical trial to evaluate the combination of stenoparib, a dual PARP/Wnt pathway inhibitor, with temozolomide for patients with recurrent Small Cell ...

Europe’s drug regulatory agency has given Kizfizo a negative opinion for the second time, following one from November 2024.

Trial to explore novel combination therapy for patients with recurrent Small Cell Lung Cancer who have failed frontline treatmentFully funded by the U.S. Veterans’ Administration Special Emphasis Pane ...

Coventry and Warwickshire’s leading medical negligence practitioners, is offering its professional support to patients ...

Orphelia Pharma is exploring alternative regulatory pathways for KIZFIZO after receiving a negative opinion from the ...

As previously disclosed on November 14, 2024, Allarity’s (ALLR) cash position is expected to support operations into 2026. The $2.5 million ...

Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company ...

NeOnc claims that its novel intranasal delivery platform will be able to bypass the blood-brain barrier and better target cancer cells.